Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALEXANDER TORRES

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1992827315
CMS profile
317250
Location
AVON PARK, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,617.08

196 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,617.08 196

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALEXANDER TORRES

NPI 1992827315 · CMS profile ID 317250

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

AVON PARK, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992827315?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALEXANDER TORRES, NPI 1992827315, CMS profile ID 317250. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992827315?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ALEXANDER TORRES, NPI 1992827315, CMS profile ID 317250. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992827315?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ALEXANDER TORRES, NPI 1992827315, CMS profile ID 317250, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 196 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1992827315?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

196 matching records · $2,617.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 196 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 196.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $3.3309/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788903721 CMS
UCB, Inc. $7.6109/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807466829 CMS
Amgen Inc. $12.7409/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123285 CMS
PFIZER INC. $13.8609/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833202681 CMS
PFIZER INC. $1.7209/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833203101 CMS
Amgen Inc. $3.1609/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123281 CMS
Horizon Therapeutics plc $9.9809/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797219391 CMS
GlaxoSmithKline, LLC. $11.0409/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802272865 CMS
Janssen Biotech, Inc. $0.6509/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788903717 CMS
Janssen Biotech, Inc. $14.3209/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788903719 CMS
Mallinckrodt Hospital Products Inc. $23.1409/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845382787 CMS
E.R. Squibb & Sons, L.L.C. $1.0509/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783500081 CMS
E.R. Squibb & Sons, L.L.C. $3.6309/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783500083 CMS
E.R. Squibb & Sons, L.L.C. $8.8309/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783500085 CMS
Mallinckrodt Hospital Products Inc. $8.0709/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845382785 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.2809/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763728708 CMS
Amgen Inc. $10.6708/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826289231 CMS
UCB, Inc. $13.3808/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807385977 CMS
Radius Health, Inc. $21.4908/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830727917 CMS
AbbVie Inc. $0.3608/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796163335 CMS
AbbVie Inc. $12.1508/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796163337 CMS
Novartis Pharmaceuticals Corporation $3.7608/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813318459 CMS
Amgen Inc. $13.9908/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123173 CMS
Amgen Inc. $10.3308/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123277 CMS
Mallinckrodt Hospital Products Inc. $15.7908/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845382783 CMS
Amgen Inc. $6.3008/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123295 CMS
AbbVie Inc. $0.3908/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796163331 CMS
AbbVie Inc. $9.6208/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796163333 CMS
Amgen Inc. $23.4908/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826289227 CMS
Amgen Inc. $12.2608/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826289223 CMS
Novartis Pharmaceuticals Corporation $24.4208/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813318455 CMS
E.R. Squibb & Sons, L.L.C. $19.7008/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783500067 CMS
PFIZER INC. $10.4508/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832635189 CMS
Amgen Inc. $17.1408/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123275 CMS
PFIZER INC. $10.8008/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832795675 CMS
AstraZeneca Pharmaceuticals LP $16.6507/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829409723 CMS
BioCryst US Sales Co., LLC $14.0507/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849110403 CMS
UCB, Inc. $14.4507/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807377171 CMS
Janssen Biotech, Inc. $3.5707/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788903703 CMS
Janssen Biotech, Inc. $5.6307/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788903705 CMS
Amgen Inc. $11.1207/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123169 CMS
Amgen Inc. $23.9307/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123217 CMS
Amgen Inc. $10.3907/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123225 CMS
AbbVie Inc. $10.7807/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796163329 CMS
AbbVie Inc. $0.2407/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796163327 CMS
Amgen Inc. $21.0607/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123213 CMS
Amgen Inc. $19.0407/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825123269 CMS
GlaxoSmithKline, LLC. $11.2807/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802590645 CMS
AbbVie Inc. $13.5607/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796163325 CMS
Janssen Biotech, Inc. $8.2907/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788903731 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,962.87 167
PY2020 $1,922.58 132
PY2021 $2,617.08 196
PY2022 $3,034.35 214
PY2023 $3,268.05 210
PY2024 $2,853.37 159
PY2025 $5,428.04 165

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $455,146.50 36
PY2024 Principal investigator $407,722.01 71
PY2023 Recipient $42,572.73 5
PY2023 Principal investigator $328,956.51 14
PY2022 Recipient $463.00 1
PY2022 Principal investigator $57,604.19 9
PY2021 Principal investigator $185,956.30 12
PY2020 Principal investigator $89,280.18 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,841.61 12/08/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432299
Principal investigator 1 ABBVIE INC. $8,835.90 12/04/2025 Non-covered Recipient Entity
HARAC RESEARCH
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202527002
Principal investigator 1 SANOFI US SERVICES INC. $1,126.25 11/19/2025 Non-covered Recipient Entity
Harac Research Corp
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226107555
Principal investigator 1 SANOFI US SERVICES INC. $5,500.00 11/12/2025 Non-covered Recipient Entity
Harac Research Corp
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226107542
Principal investigator 1 SANOFI US SERVICES INC. $2,847.50 11/12/2025 Non-covered Recipient Entity
Harac Research Corp
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226107548
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $18,399.96 11/07/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432285
Principal investigator 1 ABBVIE INC. $7,286.40 11/05/2025 Non-covered Recipient Entity
HARAC RESEARCH
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202522095
Principal investigator 1 ABBVIE INC. $9,049.50 10/09/2025 Non-covered Recipient Entity
HARAC RESEARCH
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202515275
Principal investigator 1 SANOFI US SERVICES INC. $6,506.20 10/08/2025 Non-covered Recipient Entity
Harac Research Corp
Phase 2a, Randomized, Double-blind, Placebo-controlled Trial of PRV-3279 EVAluation In Lupus (PREVAIL-2) No dispute reported 06/30/2026 1226107449
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $70,005.87 10/08/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432294
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $172.52 09/16/2025 Non-covered Recipient Entity
HARAC Research Corp
INSPIRE LTE study No dispute reported 06/30/2026 1246432332
Principal investigator 1 ABBVIE INC. $7,026.15 09/04/2025 Non-covered Recipient Entity
HARAC RESEARCH
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202509784
Principal investigator 1 ABBVIE INC. $2,027.30 09/03/2025 Non-covered Recipient Entity
HARAC RESEARCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202508192
Principal investigator 1 ABBVIE INC. $12,962.00 08/05/2025 Non-covered Recipient Entity
HARAC RESEARCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202502102
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $243.80 07/26/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432327
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $47,029.00 07/11/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432278
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $593.88 07/10/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432324
Principal investigator 1 ABBVIE INC. $11,074.00 07/02/2025 Non-covered Recipient Entity
HARAC RESEARCH
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202494965
Principal investigator 1 ABBVIE INC. $36,187.40 07/02/2025 Non-covered Recipient Entity
HARAC RESEARCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202494967
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $49,553.77 06/11/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432274
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $509.50 06/11/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432320
Principal investigator 1 ABBVIE INC. $4,054.60 05/06/2025 Non-covered Recipient Entity
HARAC RESEARCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202481819
Principal investigator 1 Eli Lilly and Company $3,295.00 04/09/2025 Non-covered Recipient Entity
HARAC RESEARCH
TALTZ PSA OBSERVATIONAL STUDY No dispute reported 06/30/2026 1187883244
Principal investigator 1 ABBVIE INC. $10,236.00 04/03/2025 Non-covered Recipient Entity
HARAC RESEARCH
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202473976
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $20,952.67 03/17/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432281
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $23,382.67 03/14/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432265
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,881.48 03/13/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432316
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,669.30 03/10/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432261
Principal investigator 1 ABBVIE INC. $6,257.40 03/07/2025 Non-covered Recipient Entity
HARAC RESEARCH
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202460911
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $228.75 02/11/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432311
Principal investigator 1 ABBVIE INC. $11,290.90 02/06/2025 Non-covered Recipient Entity
HARAC RESEARCH
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202449301
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $34,651.80 02/03/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432289
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $195.04 01/23/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432307
Principal investigator 1 Eli Lilly and Company $1,259.00 01/21/2025 Non-covered Recipient Entity
HARAC RESEARCH
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187883516
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $27,545.26 01/10/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432269
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,468.12 01/10/2025 Non-covered Recipient Entity
HARAC Research Corp
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246432303